Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Na+ CP type IVα Inhibitors

Chemical inhibitors of Na+ CP type IVα include a variety of compounds that block the function of this voltage-gated sodium channel by different mechanisms. Tetrodotoxin, for example, binds to the extracellular pore of Na+ CP type IVα, directly occluding the pathway necessary for sodium ions to traverse the cell membrane. This action effectively prevents the initiation and propagation of action potentials. Similarly, saxitoxin operates by selectively attaching to the sodium channels on nerve cell membranes, also blocking the sodium influx essential for action potential generation. Lidocaine, another inhibitor, targets these channels as well, but it acts by preventing the conduction of nerve impulses, which is a common mechanism among local anesthetics. Phenytoin and carbamazepine share a related inhibitory effect on Na+ CP type IVα; they prolong the inactive state of these channels, thus reducing their ability to transition back to an active state, which decreases neuronal excitability.

In the second group of inhibitors, lamotrigine also blocks the Na+ CP type IVα channel but does so by specifically diminishing glutamate release, which is critical for the stabilization of neuronal membranes. Riluzole, while modulating glutamatergic transmission, inhibits the channels by reducing excitotoxicity, a detrimental neuronal condition. Other inhibitors such as ranolazine, lorcainide, and mexiletine focus particularly on cardiac cells, where they inhibit Na+ CP type IVα by altering the action potential characteristics, thereby reducing cellular excitability. Lastly, propafenone functions by decelerating the velocity of the cardiac action potential through its blockade of Na+ CP type IVα, which affects the heart muscle's excitability and conductivity, ensuring that electrical impulses are moderated. Each chemical exhibits a specific mode of action but converges on the common outcome of functionally inhibiting the Na+ CP type IVα channel, thus directly affecting the flow of sodium ions and the electrical signaling in cells.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Lidocaine

137-58-6sc-204056
sc-204056A
50 mg
1 g
$51.00
$131.00
(0)

Lidocaine is a local anesthetic that inhibits Na+ CP type IVα by blocking the voltage-gated Na+ channels in neurons, which prevents the generation and conduction of nerve impulses.

5,5-Diphenyl Hydantoin

57-41-0sc-210385
5 g
$70.00
(0)

Phenytoin inhibits Na+ CP type IVα by prolonging the inactivated state of voltage-gated sodium channels, thus reducing the ability of these channels to recover from inactivation and reducing neuronal excitability.

Carbamazepine

298-46-4sc-202518
sc-202518A
1 g
5 g
$33.00
$71.00
5
(0)

Carbamazepine inhibits Na+ CP type IVα by stabilizing the inactive state of voltage-gated sodium channels, thereby reducing the repetitive firing of action potentials.

Lamotrigine

84057-84-1sc-201079
sc-201079A
10 mg
50 mg
$120.00
$486.00
1
(1)

Lamotrigine selectively inhibits Na+ CP type IVα by blocking voltage-sensitive sodium channels, which diminishes glutamate release and stabilizes neuronal membranes.

Riluzole

1744-22-5sc-201081
sc-201081A
sc-201081B
sc-201081C
20 mg
100 mg
1 g
25 g
$20.00
$193.00
$213.00
$317.00
1
(1)

Riluzole inhibits Na+ CP type IVα by modulating glutamatergic neurotransmission through its inhibitory effects on voltage-gated sodium channels, which leads to reduced excitotoxicity.

Ranolazine

95635-55-5sc-212769
1 g
$109.00
3
(1)

Ranolazine inhibits Na+ CP type IVα by selectively blocking late phase of the inward sodium current during cardiac repolarization, thus reducing intracellular calcium overload and preventing excessive excitability.

Propafenone Hydrochloride

34183-22-7sc-204863
sc-204863A
sc-204863B
sc-204863C
1 g
5 g
25 g
100 g
$21.00
$66.00
$198.00
$501.00
(1)

Propafenone inhibits Na+ CP type IVα by blocking voltage-gated sodium channels, leading to slowed conduction velocity of the cardiac action potential, hence decreasing the excitability and conductivity of the heart muscle.